NPC1 as a Modulator of Disease Severity and Viral Entry of SARS-CoV-2

dc.contributor.author	Vial, Cecilia
dc.contributor.author	Calderón, Juan Francisco
dc.contributor.author	Klein, Andrés
dc.date.accessioned	2021-08-17T16:56:37Z
dc.date.available	2021-08-17T16:56:37Z
dc.date.issued	2020
dc.description.abstract	The COVID-19 plague is hitting mankind. Several viruses, including SARS-CoV-1, MERS-CoV, EBOV, and SARS-CoV-2, use the endocytic machinery to enter the cell. Genomic variants in NPC1, which encodes for the endo-lysosomal Niemann-Pick type C1 protein, restricts the host-range of viruses in bats and susceptibility to infections in humans. Lack of NPC1 and its pharmacological suppression inhibits many viral infections including SARS-CoV-1 and Type I Feline Coronavirus Infection. Antiviral effects of NPC1-inhibiting drugs for COVID-19 treatment should be explored.	es
dc.identifier.citation	Current Molecular Medicine, 2020, 20: 1-3	es
dc.identifier.uri	https://dx.doi.org/10.2174/1566524020666200713175426	es
dc.identifier.uri	http://hdl.handle.net/11447/4342
dc.language.iso	en	es
dc.subject	COVID-19	es
dc.subject	SARS-Cov-2	es
dc.subject	Niemann-Pick C1	es
dc.subject	Modifier gene	es
dc.subject	Drug repurposing	es
dc.subject	Virus	es
dc.subject	Infection	es
dc.title	NPC1 as a Modulator of Disease Severity and Viral Entry of SARS-CoV-2	es
dc.type	Article	es

Files

Now showing 1 - 1 of 1

Name:: NPC1 as a modulator of disease severity and viral entry of Sars-CoV-2 - Andrés Klein.pdf
Size:: 246.01 KB
Format:: Adobe Portable Document Format
Description:: Texto completo

Now showing 1 - 1 of 1